Sponsors
Meet Our Event Sponsors
Our line-up of visionary companies ready to connect with you, offering leading technologies and solutions to advance your biomarker research.
Discovery Europe 2024
Gold Sponsors
bit.bio is a synthetic biology company focused on human cells that is advancing medicine and enabling curative treatments.
bit.bio's opti-ox™ precision cell programming technology enables conversion of induced pluripotent stem cells (iPSCs) into any desired human cell type in a single step, at industrial scale, while maintaining exceptional purity and consistency.
bit.bio’s cell therapy pipeline, based on txCellsTM, is focused on serious diseases that lack effective treatments. The lead candidate, bbHEP01 based on txHepatocytes, is in development as a treatment for patients suffering from acute liver failure and acute-on-chronic liver failure.
The ioCells™ research cell product portfolio is opening up new possibilities for studying human biology and developing new medicines in research and drug discovery.
bit.bio's opti-ox™ precision cell programming technology enables conversion of induced pluripotent stem cells (iPSCs) into any desired human cell type in a single step, at industrial scale, while maintaining exceptional purity and consistency.
bit.bio’s cell therapy pipeline, based on txCellsTM, is focused on serious diseases that lack effective treatments. The lead candidate, bbHEP01 based on txHepatocytes, is in development as a treatment for patients suffering from acute liver failure and acute-on-chronic liver failure.
The ioCells™ research cell product portfolio is opening up new possibilities for studying human biology and developing new medicines in research and drug discovery.
Our mission at Causaly is to redefine the boundaries of human discovery by harnessing transformative AI technologies. Founded in 2018, Causaly’s unique AI platform is a powerful catalyst for the modern Life Sciences research organization, reshaping how data is found, analyzed and applied in critical decision-making processes during drug discovery and development. Supporting a broad range of complex knowledge workflows, our platform accelerates the journey from bench research and laboratory insights to the launch of life-changing therapies. For more information, please visit www.causaly.com
Silver Sponsors
Ardigen, a world-leading AI CRO, stands at the forefront of enabling AI transformation for the biotech and pharmaceutical sectors. Our objective is to increase the probability of success in the drug development process. We utilize our advanced platforms and deep expertise to turn vast amounts of data into pivotal, ready-to-use scientific insights. Leveraging our expertise, we also enhance the infrastructure that allows our clients to integrate and utilize these capabilities seamlessly within their organizations. More information at ardigen.com
Trusted by over one million active users, Chemaxon is renowned for industry-leading software supporting scientific discovery with calculation, search and drawing tools. Our applications are widely used in life sciences R&D and education. We work with a variety of industries, counting most major pharmaceutical companies among our clients. Our offices are located in Budapest, Basel, Boston and San Diego, with distributors around the world.
Optibrium develops exceptional software and AI solutions that help scientists advance their discovery projects. Cutting-edge science, backed up by rigorous research, underpins their intuitive software for compound design, optimisation and data analysis. Optibrium’s comprehensive in silico platform improves the speed, efficiency, and productivity of the discovery process and supports a worldwide customer base, including leading pharma, biotech, agrochemical and flavouring companies and not-for-profit and academic groups. Optibrium was founded in 2009 and is headquartered in Cambridge, UK, with a US subsidiary, Optibrium Inc., based in Cambridge MA.
Pelago Bioscience is a Drug Discovery Research Partner supporting preclinical drug discovery and development with our expertise in biologically relevant assay systems. Our unique core technology, the Cellular Thermal Shift Assay (CETSA® by Pelago Bioscience), has multiple assay formats that make it a keystone of decision-making throughout the drug discovery pipeline. We offer a range of customized services, from confirming target engagement to strengthening target validation and understanding the mechanism of action of your compounds. Our approach is designed to help you make better decisions faster, no matter where you are in the drug discovery process.
Pivot Park Screening Centre is a Dutch company that offers services in assay development, lab automation, ultra-High Throughput Screening (uHTS) and hit-to-lead profiling, in order to find novel hits for drug development. We develop and miniaturize high-quality cellular, biochemical and biophysical primary, deselection, orthogonal and selectivity assays across various target classes and disease areas, and have carried out almost 250 full-deck uHTS campaigns across libraries ranging ~0.3-1.5 million compounds, using label-based and label-free (MALDI-MS) readouts, mostly in 1,536-well plate format. You can either bring your own compound library or use our 300K IP-free druglike compound library. Pivot Park Screening Centre is located on the Life Sciences Campus Pivot Park, the former research site of MSD in the Netherlands, which focuses on pharmaceutical R&D.
Sapient is a biomarker discovery organization providing bespoke services for metabolomics, lipidomics, and proteomics data generation and analysis, enabling biopharma sponsors to go beyond the genome to accelerate precision drug development. Using state-of-the-art, high-throughput mass spectrometry technologies, Sapient enables nontargeted multi-omics measurements to capture thousands of dynamic biomarkers in human, preclinical, and cellular biosamples, across thousands of samples at a time. These technologies are leveraged within a larger discovery infrastructure that includes a comprehensive biocomputational framework for analysis of large-scale, multi-omics data;robust quality control analysis;and mapping of key biomarker-phenotype associations. Sapient can cross-validate discoveries using our proprietary in-house longitudinal Human Biology Database that includes data from over 100,000 human biosamples with paired phenotypic measures. Together our approaches enable rapid identification, validation, and translation of dynamic biomarkers of biological processes, disease mechanisms, and drug response across all drug development phases.
XtalPi is a global technology platform company powered by artificial intelligence (AI) and robotics. Founded in 2015, XtalPi is dedicated to driving intelligent and digital transformation in life sciences and discovering better therapeutics and new materials. By integrating and synergizing quantum physics, AI, cloud computing, and large-scale clusters of robotic workstations, XtalPi offers a range of innovative solutions, services, and products to empower our partners in the biopharmaceutical, chemical, new energy, and new materials sectors worldwide.
Bronze Sponsors
Axxam is a leading provider of integrated discovery services across the life sciences industry. Within the drug discovery disciplines, we support pharma, biotech companies, start-ups, patient foundations as well as academic groups in their journey from hit identification to lead generation, regardless of the therapeutic area and target class. Our services include assay development, high-throughput screening, using either Axxam's high quality compound collections (synthetic and natural) or those provided by clients, hit validation, hit-to-lead and compound management. The same science-driven approach is also applied to identify new bioactive compounds for crop protection, animal health, food, beverage, pet food, cosmetic and perfume industries.
Based in Charleroi, Belgium, EuroscreenFast has been a pioneer in GPCR science for more than 30 years. As the first company to offer access to recombinant GPCR assays, EuroscreenFast has grown to offer a catalogue that includes over 1,000 functional assays representing more than 530 GPCR and other targets. Therapeutic developers worldwide trust EuroscreenFast with their compounds to determine affinity, potency, efficacy and functional selectivity.
Beyond binding & functional GPCR screening, EuroscreenFast also boasts an impressive deorphanisation track record with the identification of 17 natural receptor-ligand pairs. Resulting in 12 patents, this world leading platform is based on a unique collection of natural tissue extracts, a large library of cellular tools and more than three decades in the field. The company has one of the largest libraries of orphan GPCR cell lines, verified for receptor expression.
Custom cell line and assay development is also core to the offering at EuroscreenFast. Using a proprietary high-copy, bicistronic expression vector, cell lines from a range of species can be engineered to express the client’s target of choice and validated for use in functional or binding assays, or as a screening tool for drug discovery. EuroscreenFast has also developed specialized assays to bridge the gap between in vitro and in vivo data.
The team of highly skilled and expert scientists strategically design each program based on the latest knowledge of the target’s biology – EuroscreenFast is your unrivalled GPCR development partner.
EuroscreenFast is a business unit of EPICS Therapeutics SA.
Beyond binding & functional GPCR screening, EuroscreenFast also boasts an impressive deorphanisation track record with the identification of 17 natural receptor-ligand pairs. Resulting in 12 patents, this world leading platform is based on a unique collection of natural tissue extracts, a large library of cellular tools and more than three decades in the field. The company has one of the largest libraries of orphan GPCR cell lines, verified for receptor expression.
Custom cell line and assay development is also core to the offering at EuroscreenFast. Using a proprietary high-copy, bicistronic expression vector, cell lines from a range of species can be engineered to express the client’s target of choice and validated for use in functional or binding assays, or as a screening tool for drug discovery. EuroscreenFast has also developed specialized assays to bridge the gap between in vitro and in vivo data.
The team of highly skilled and expert scientists strategically design each program based on the latest knowledge of the target’s biology – EuroscreenFast is your unrivalled GPCR development partner.
EuroscreenFast is a business unit of EPICS Therapeutics SA.
The NUVISAN group is a contract research and development and manufacturing organization (CRO/CDMO) with five sites in Germany and France as well as local experts situated in Latin America. We offer unique, high-quality, and tailored integrated solutions along the drug discovery and development value chain to our biotech startup, pharma, non-profit, and venture capital clients – from target identification to the patient. With more than 40 years of experience and a dedicated team of over 1,000 professionals, including more than 70% industry-experienced scientists and laboratory professionals, we possess the expertise to navigate the complexities of bringing innovative medicines to market. With over four decades of experience and a dedicated team of over 1,000 professionals, including more than 70% industry-experienced scientists and laboratory professionals, we possess the expertise to navigate the complexities of bringing innovative medicines to market. Recognizing the unique nature of each project, our teams prioritize flexible and innovative approaches and foster transparent communication to work closely with clients and effectively meet individual needs. Our services can be provided as stand-alone or integrated solutions and can be customized to your project.
We enable life scientists to unlock the mysteries of biological complexity with cryo-electron microscopy (Cryo-EM). This invaluable technique provides structural insights for a wide range of intractable targets and has become integral to structure-based design. By enabling structure determinations of proteins and macromolecular complexes in near native states and the characterization of drug delivery systems, cryo-EM provides insights benefitting all stages in drug discovery from target evaluation through process development.
Network & Programme Sponsors
Aurigene Pharmaceutical Services is a global contract research, development, and manufacturing organization (CRDMO). Built on the legacy of accelerating innovation and backed by a vast track record in drug discovery, development, and manufacturing of small and large molecules, our mission is to work for the success of our clients relentlessly and to build long-term relationships through a holistic approach to accelerate the journey of a molecule from the laboratory to market. We offer integrated and standalone services for discovery chemistry, biotherapeutics discovery, discovery biology, development, and manufacturing services for clinical phase I-III programs, regulatory submission batches, and commercial manufacturing. What sets Aurigene apart is the integrated API and formulations service that spans from key starting material, advanced intermediates, and APIs to finished products such as oral solids, sterile products, nasal solutions, etc. GMP commercial manufacturing facilities in the UK, Mexico, US, and India complement our development and pharmaceutical API manufacturing services in India.
For more information log on to: https://www.aurigeneservices.com/ or email us at: ContactAPSL@aurigeneservices.com
For more information log on to: https://www.aurigeneservices.com/ or email us at: ContactAPSL@aurigeneservices.com
Bioneer A/S is an innovative CRO creating customised research services academic and industry partners. We specialize in offering stem cell-related services such as reprogramming, CRISPR gene editing, neuronal differentiation, and image-based assay and screening services. With our highly skilled employees, state-of-the-art laboratory facilities, we help develop better in vitro models for understanding neurodegenerative diseases.
Through our platform, Galactic AI™, we use artificial intelligence-led curation to enable the insights that matter to scientists and organisations developing the medical innovations of the future. We provide the most advanced data curation and the most novel knowledge graph of rich cause-and-effect and contextual data available in biopharma.
BrainXell provides high-purity, iPSC-derived human neurons and glia for translational research and drug discovery. Utilizing proprietary technology, we generate high-purity, subtype-specific neurons that mature rapidly and are quickly and easily ready for a variety of assays. Multiple neuron subtypes relevant to a range of disorders are available. Additionally, each neuron subtype can be made in custom batches from 50 million to 10 billion neurons from unique iPSC lines. We are dedicated to delivering the highest quality products for off-the-shelf neurons and custom service projects.
At Cellectricon, we create new avenues for neuroscience drug discovery. Our mission is to create ground-breaking concepts that will advance the neuroscience research field.
From early concept evaluation to transformative drug discovery campaigns, we solve your scientific challenges through innovative approaches for in vitro research.
• Obtain new insights into disease biology
• Accelerate the R&D process and reduce time-to-decision making
• Identify targets and lead compounds with potential to produce first-in-class medicines
Our unique discovery platform combines drug discovery expertise and disease area knowledge with cutting-edge technologies. With the platform, we are creating complex disease models and assays for functional and morphological screening.
We have established service modules in the areas of Peripheral Neuropathies, Neurodegeneration, Neuroplasticity and Neuroinflammation. Through our services, we can accelerate your target and lead discovery programs.
From early concept evaluation to transformative drug discovery campaigns, we solve your scientific challenges through innovative approaches for in vitro research.
• Obtain new insights into disease biology
• Accelerate the R&D process and reduce time-to-decision making
• Identify targets and lead compounds with potential to produce first-in-class medicines
Our unique discovery platform combines drug discovery expertise and disease area knowledge with cutting-edge technologies. With the platform, we are creating complex disease models and assays for functional and morphological screening.
We have established service modules in the areas of Peripheral Neuropathies, Neurodegeneration, Neuroplasticity and Neuroinflammation. Through our services, we can accelerate your target and lead discovery programs.
Concept Life Sciences, a collaborative client-centred approach. We are a multi-disciplined Contract Research Organisation based in the UK providing market-leading scientific services globally. Over the past 25 years, Concept Life Sciences and its heritage companies have played a pivotal role in guiding numerous clients along their path to clinical success and many of these clients have evolved into enduring scientific collaborators. Within a decade, the collaborative efforts of experts from our heritage businesses — Peakdale Molecular, CXR Biosciences, and Aquila Biomedical — have propelled us beyond the cumulative impact of our individual components, fostering substantial growth and advancement. We are based across 4 research sites in the UK delivering discovery research, as well as GMP, GLP, and GCP-regulated work. Whether it is delivering whole programs of research, or bespoke studies, we deliever a a collaborative client-centred approach. Our services include discovery chemistry, specialist translational biology for immunology, oncology and neuroscience, biologics, biophysical assays services, ADMET & DMPK, bioanalysis, toxicology, histology, analytical services, including materials characterisation and physiochemical analysis, process research and development, and GMP manufacturing.
IRBM is a scientific contract research organization (CRO) that stands at the forefront of drug discovery, leveraging a single, unified research facility to accelerate team-based breakthroughs and improve efficiencies from concept to candidate. With a history of contributing to four approved drugs, an internal pipeline of oncology and other therapeutic assets (including a brain-permeable SHP2 inhibitor for aggressive brain tumors and metastases), and decades of experience in contributing to drug discovery projects in neurodegenerative diseases for third parties including a recently announced multi-year drug discovery collaboration to identify small molecule cGAS inhibitors for treating neurodegenerative diseases including Alzheimer’s, IRBM is powered by deep collaborations and scientific expertise from leading global institutions. Their comprehensive in-house capabilities assist partners in achieving key milestones and progressing towards clinical readiness, positioning IRBM as a major player in driving innovation in the pharmaceutical and biotech fields.
Luminex Corporation develops, manufactures, and sells proprietary technology, assays, and systems that empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. Our Molecular Diagnostics (MDx) and Life Science and Clinical Tools portfolios provide cost-effective, flexible solutions for hospitals, reference labs, and researchers, as well as innovative xMAP® and flow cytometry solutions that span a wide variety of applications, including molecular diagnostics, drug discovery, life science research, immunology, personalized medicine, cellular analysis, and more. Our goal is to transform global healthcare with innovative technology that delivers rapid, reliable results to clinicians and researchers. Most recently, we have been actively focused on providing diagnostic tests for SARS-CoV-2, with two diagnostic tests currently on the market. We are also pursuing several additional options in serology testing. For further information, please visit luminexcorp.com/
Proscia is a software company that is accelerating pathology’s transformation toward a data-driven discipline. Our Concentriq® enterprise digital pathology platform and powerful AI applications are unlocking new insights that accelerate discovery, improve patient outcomes, and fulfill the promise of precision care.
For 25 years, Sai Life Sciences has been a trusted partner in bringing new medicines to life, fast. As a global Contract Research, Development & Manufacturing Organization (CRO-CDMO), the company works with innovator biotech and pharma companies to accelerate the discovery, development and commercialization of complex small molecules. Taking a nimble and creative approach, Sai delivers high-quality, cost-eff¬ective solutions to accelerate their time to market.
With over 3000 employees across facilities in India, UK and USA, it supports innovators across the entire drug discovery journey from concept to commercialisation, including exploratory biology, creative chemistry, DMPK, toxicology, developability & formulations, early phase development, process & analytical development, scale-up, tech transfer, clinical supplies and cGMP manufacturing.
Sai builds lasting partnerships with its clients through collaboration. Today, it serves 300+ companies, spanning start-ups, small & mid-sized pharma, and large pharma across US, UK, EU and Japan and count among its clients 17 of the top 20 large pharma companies by market capitalization.
Sai’s Discovery services are designed to accelerate the journey from ‘Concept to Clinic’ through speed & high-quality data by bringing together Medicinal Chemistry, Biology, DMPK, Toxicology under one roof to fast-track the DMTA (Design, Make, Test and Analyze) cycle. The company’s global delivery model delivers unique value to its customers through an optimal blend of talent, speed, and cost efficiency. The company has completed over 200 Discovery programs across Oncology, CNS, Inflammation, Antivirals, Rare diseases, and more.
With over 3000 employees across facilities in India, UK and USA, it supports innovators across the entire drug discovery journey from concept to commercialisation, including exploratory biology, creative chemistry, DMPK, toxicology, developability & formulations, early phase development, process & analytical development, scale-up, tech transfer, clinical supplies and cGMP manufacturing.
Sai builds lasting partnerships with its clients through collaboration. Today, it serves 300+ companies, spanning start-ups, small & mid-sized pharma, and large pharma across US, UK, EU and Japan and count among its clients 17 of the top 20 large pharma companies by market capitalization.
Sai’s Discovery services are designed to accelerate the journey from ‘Concept to Clinic’ through speed & high-quality data by bringing together Medicinal Chemistry, Biology, DMPK, Toxicology under one roof to fast-track the DMTA (Design, Make, Test and Analyze) cycle. The company’s global delivery model delivers unique value to its customers through an optimal blend of talent, speed, and cost efficiency. The company has completed over 200 Discovery programs across Oncology, CNS, Inflammation, Antivirals, Rare diseases, and more.
Selvita is one of the leading preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development.
Selvita provides comprehensive solutions supporting Clients and their drug discovery projects, across a broad range of therapeutic areas, specializing in infectious diseases, inflammation, fibrosis, and oncology. The Company offers a range of stand-alone or fully integrated drug discovery and development solutions spanning the entire value chain from early drug discovery to preclinical development, both for small molecules and therapeutic antibodies. On top of that, Selvita also offers analytical support for drug development and contract testing studies.
Selvita, established in 2007, operates globally with over 900 highly qualified employees, of which over 40% hold a PhD degree. The Company's research sites are in Krakow (HQ), Poznan and Wroclaw Poland, and Zagreb, Croatia. The international offices are located in Cambridge, MA, and San Francisco Bay Area, in the U.S., as well as in Cambridge, UK. Selvita is listed on the Warsaw Stock Exchange (WSE: SLV). For more information, please see www.selvita.com.
Selvita provides comprehensive solutions supporting Clients and their drug discovery projects, across a broad range of therapeutic areas, specializing in infectious diseases, inflammation, fibrosis, and oncology. The Company offers a range of stand-alone or fully integrated drug discovery and development solutions spanning the entire value chain from early drug discovery to preclinical development, both for small molecules and therapeutic antibodies. On top of that, Selvita also offers analytical support for drug development and contract testing studies.
Selvita, established in 2007, operates globally with over 900 highly qualified employees, of which over 40% hold a PhD degree. The Company's research sites are in Krakow (HQ), Poznan and Wroclaw Poland, and Zagreb, Croatia. The international offices are located in Cambridge, MA, and San Francisco Bay Area, in the U.S., as well as in Cambridge, UK. Selvita is listed on the Warsaw Stock Exchange (WSE: SLV). For more information, please see www.selvita.com.
Symeres is a leading transatlantic integrated drug discovery and development CRO/CDMO driving your programmes from hit to clinic. With over 600 scientists located in Europe and the USA we tackle challenges in medicinal chemistry with world-class disease area and target class expertise, skilfully employing computational, parallel chemistry technologies where it matters.
ADME/tox and PK profiling is delivered by our dedicated Admescope platform, biochemical and cellular assays, including cancer cell line screening by our Oncolines in vitro oncology platform.
We can support hit finding via HTS with our proprietary "SymeGold" library, but also fragment-based approaches;virtual screening;scaffold hopping and other techniques. A particular strength of ours lies in the transition from research to development with our large expert team providing creative route scouting and Process R&D solutions, leading to an efficient and fit for purpose GMP API production for clinical Phase 1 and Phase II studies. This includes formulation development and solid-form drug product supply for tox and Phase I studies.
Synthesis of challenging compounds such as macrocycles, chiral compounds, lipids, complex carbohydrates, ADCs, degraders, isotopically labelled compounds is in the DNA of Symeres with decades of experience.
We have been key to our partners' success for over 30 years. We bring deep scientific knowledge and creativity to your project goals. We make your molecules matter.
ADME/tox and PK profiling is delivered by our dedicated Admescope platform, biochemical and cellular assays, including cancer cell line screening by our Oncolines in vitro oncology platform.
We can support hit finding via HTS with our proprietary "SymeGold" library, but also fragment-based approaches;virtual screening;scaffold hopping and other techniques. A particular strength of ours lies in the transition from research to development with our large expert team providing creative route scouting and Process R&D solutions, leading to an efficient and fit for purpose GMP API production for clinical Phase 1 and Phase II studies. This includes formulation development and solid-form drug product supply for tox and Phase I studies.
Synthesis of challenging compounds such as macrocycles, chiral compounds, lipids, complex carbohydrates, ADCs, degraders, isotopically labelled compounds is in the DNA of Symeres with decades of experience.
We have been key to our partners' success for over 30 years. We bring deep scientific knowledge and creativity to your project goals. We make your molecules matter.
Automate Europe 2024
Gold Sponsors
Silver Sponsors
Founded in 2012, ESSERT Robotics is an innovation leader in the field of flexible, modular and scalable automation. The company develops highly standardised robot automation modules which, combined with various process modules, form the ESSERT MicroFactory, a scalable production platform with a clear focus on low-volume / high-mix production. With advanced robotic technologies, ESSERT supports customers in the pharmaceutical and life science industries, as well as in general industry, with the challenges of producing increasingly individualised products. For further information please visit: www.essert.com
Bronze Sponsors
Collaborative Drug Discovery (CDD) provides an intuitive software suite extensively used by creative biologists and chemists working in academic, biotechnology and pharmaceutical settings. Their flagship product, CDD Vault, enables researchers to intuitively organize and analyze both biological and chemical data, and to collaborate with partners through a straightforward web interface. CDD Vault helps scientists register entities, track inventory, manage bioassay data, capture experiments, calculate Structure-Activity Relationships (SAR), and mine their data for drug candidates. It also functions as an Electronic Laboratory Notebook (ELN) to capture and share experimental results. CDD Vault is differentiated through its intuitive design, superior performance, and workflows for secure, collaborative data sharing capabilities. CDD was founded in 2004 and presently serves thousands of researchers doing drug discovery all around the world. Learn more at www.collaborativedrug.com
Rapid Micro Biosystems® (RMB) creates, sells, validates, and services innovative products for fast, accurate, and efficient detection of microbial contamination in the manufacture of cell and gene therapies, pharmaceuticals, biologics, biotechnology products, medical devices, and personal care products. The company’s Growth Direct® is the only fully automated, non-destructive growth-based system for multiple QC test applications: environmental monitoring, water, bioburden, and sterility testing. Automating rapid compendial QC micro testing ensures data integrity, compliance, and operational efficiencies. RMB is dedicated to providing groundbreaking technology and products to support companies in their journey to achieve greater reliability, efficiency, and better predictability, ultimately providing higher quality products for improved patient outcomes.
Network & Programme Sponsors
Axel Semrau GmbH byTrajan Trajan Scientific and Medical's acquisition of Axel Semrau GmbH in 2021 has significantly enhanced their capabilities in automation, chromatography, and software solutions. This merger combines Trajan's strength in North America with Axel Semrau's focus in Europe, particularly in the food and environmental markets. Together, they aim to provide comprehensive workflow systems globally under the CHRONECT brand, utilizing Axel Semrau's CHRONOS software. With over 40 years of experience, they specialize in automating complex laboratory workflows, integrating sample preparation and analysis techniques for GC-MS and LC-MS. Their solutions cater to various industries, including food, pharmaceuticals, and clinical sectors. The success of their products relies on the dedication of their diverse team, comprising experts in chemistry, biology, IT, and economics. Trajan's global presence spans across multiple continents, with a workforce of over 600 people and manufacturing sites in the US, Australia, Europe, and Malaysia. Their mission of "Science that benefits people" drives their commitment to providing innovative scientific tools and solutions. For more information, visit www.trajanscimed.com or www.axelsemrau.com. Contact Axel Semrau GmbH at info@axelsemrau.de or visit their headquarters in Sprockhövel, Germany.
FORMULATRIX® collaborates with researchers to simplify the preparation and analysis of proteins and nucleic acids by designing solutions without boundaries and bringing cutting-edge technology to the life science industry. We supply software and laboratory automation solutions to the top pharmaceutical companies and leading academic research institutions working in a variety of genomics and proteomics applications. We are committed to researchers, labs, and to the scientific discoveries that will improve the lives of generations to come.
Our extensive and engaged community extends across large, mid-size and innovative start-ups within the pharma and biotech space, with a dedicated audience spanning a range of specialisms. Whether you have content to share, are looking for ways to enhance your brand visibility or would like to increase engagement with prospective customers, Oxford Global can offer valuable access to your target demographic through our range of event & content services.
-
Amplify your reach through a tailored presence at our high-level events
-
Digital Services
Create dedicated digital sessions designed to attract your target audience -
Lead Generation
Curated environments designed to create meaningful conversations -
Content Services
Create exposure and drive messaging to target demographics -
Event Management
Bespoke event creation, management and marketing built to your design